<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63822">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01981837</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTRSC-002</org_study_id>
    <nct_id>NCT01981837</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Evaluate ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis</brief_title>
  <official_title>A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and
      exploratory clinical activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac
      Amyloidosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation.</measure>
    <time_frame>Up to 63 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ALN-TTRSC (Cmax, tmax, t1/2, AUC, CL, Vss, Vz)</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALN-TTRSC on transthyretin (TTR) (Determination of % Lowering of TTR to pretreatment/Baseline Levels)</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>TTR-mediated Amyloidosis</condition>
  <arm_group>
    <arm_group_label>ALN-TTRSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-TTRSC for subcutaneous administration</intervention_name>
    <arm_group_label>ALN-TTRSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TTR cardiac amyloidosis;

          -  Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot
             be breast feeding, and must be willing to use 2 highly effective methods of
             contraception;

          -  Male subjects agree to use appropriate contraception;

          -  Adequate blood counts, liver, renal and heart function;

          -  Adequate Karnofsky performance status;

          -  Adequate New York Heart Association (NYHA) Classification Score;

          -  Clinically stable on heart medications;

          -  Adequate 6-minute walk test;

          -  Willing to give written informed consent and are willing to comply with the study
             requirements.

        Exclusion Criteria:

          -  Known human immunodeficiency virus (HIV) positive status or known or suspected
             systemic bacterial, viral, parasitic, or fungal infection;

          -  Subjects with a history of multiple drug allergies or intolerance to SC injection;

          -  Received an investigational agent other than tafamidis, diflunisal, doxycycline or
             tauroursodeoxycholic acid, or an investigational device within 30 days prior to first
             dose of study;

          -  Uncontrolled hypertension, ischemic heart disease or cardiac arrhythmia;

          -  Untreated hypo- or hyperthyroidism;

          -  Prior major organ transplant;

          -  Considered unfit for the study by the Principal Investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Gollob, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trials Hotline. Call for Complete Site List.</last_name>
    <phone>617-575-7400 or 1-866-330-0326</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>UK NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
